A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID:
MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
fisetin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Melatonin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]
Cisplatin results in increased expression of CASP9 mRNA; Cisplatin results in increased expression of CASP9 protein; Cisplatin results in increased expression of CASP9 protein modified form
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; ABCB1 protein inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]]; anemoside B4 inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; aucubin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; CARM1 protein affects the reaction [Cisplatin results in increased cleavage of CASP9 protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Melatonin inhibits the reaction [Cisplatin results in increased expression of CASP9 protein modified form]; Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; PARK7 protein affects the reaction [Cisplatin results in increased cleavage of CASP9 protein]; PRMT3 protein affects the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Rosmarinic Acid inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]; sarpogrelate inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]
4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin results in increased activity of CASP9 protein]]; [4-methylene-2-octyl-5-oxofuran-3-carboxylic acid co-treated with Cisplatin] results in increased activity of CASP9 protein; [andrographolide co-treated with Cisplatin] results in increased expression of CASP9 mRNA; [Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased cleavage of CASP9 protein; [Cisplatin co-treated with chrysin] results in increased cleavage of CASP9 protein; [Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein; [Cisplatin co-treated with FASLG protein] results in increased activity of CASP9 protein; [Cisplatin co-treated with fisetin] promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein]; [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP9 protein; [Deoxyglucose co-treated with Cisplatin] results in increased activity of CASP9 protein; [Fluorouracil co-treated with Cisplatin] results in increased activity of CASP9 protein; [Fluorouracil co-treated with Cisplatin] results in increased expression of CASP9 protein; [GJB1 protein co-treated with GJB2 protein] promotes the reaction [Cisplatin results in increased activity of CASP9 protein]; [Quercetin co-treated with Cisplatin] results in increased activity of CASP9 protein; [S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of CASP9 protein; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; [Sirolimus co-treated with Cisplatin] results in increased activity of CASP9 protein; [SND1 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of CASP9 protein; [TNFSF10 protein co-treated with Cisplatin] results in increased activity of CASP9 protein; ABCB1 protein inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; acetyl-leucyl-glutamyl-histidyl-aspartal inhibits the reaction [[GJB1 protein co-treated with GJB2 protein] promotes the reaction [Cisplatin results in increased activity of CASP9 protein]]; acetyl-leucyl-glutamyl-histidyl-aspartal inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [[Cisplatin co-treated with FASLG protein] results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [[S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of CASP9 protein]; Acetylcysteine inhibits the reaction [Cisplatin results in decreased expression of CASP9 protein]; Acetylcysteine inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; astilbin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; BCL2 inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; BCL2 protein inhibits the reaction [[Cisplatin co-treated with FASLG protein] results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Cisplatin co-treated with FASLG protein] results in increased activity of CASP9 protein]; beta-solamarine promotes the reaction [Cisplatin results in increased activity of CASP9 protein]; BMI1 protein inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; CAPN1 protein affects the reaction [Cisplatin results in increased cleavage of CASP9 protein]; CAPN2 protein affects the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Cisplatin results in increased cleavage of and results in increased activity of CASP9 protein; Cisplatin results in increased expression of and results in increased cleavage of CASP9 protein; CXCL2 protein promotes the reaction [Cisplatin results in increased activity of CASP9 protein]; DICER1 mutant form inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; EGR1 protein promotes the reaction [Cisplatin results in increased activity of CASP9 protein]; Eicosapentaenoic Acid promotes the reaction [Cisplatin results in increased activity of CASP9 protein]; ING4 protein promotes the reaction [Cisplatin results in increased activity of CASP9 protein]; MIR630 mRNA inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; MYC protein promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein]; Noscapine promotes the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP9 protein]; oleylamide inhibits the reaction [[GJB1 protein co-treated with GJB2 protein] promotes the reaction [Cisplatin results in increased activity of CASP9 protein]]; PRDX6 protein inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; Progesterone inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; Rutin inhibits the reaction [Cisplatin results in decreased expression of CASP9 protein]; sarpogrelate inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]; SMG1 protein inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; SND1 mutant form promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Tretinoin promotes the reaction [[GJB1 protein co-treated with GJB2 protein] promotes the reaction [Cisplatin results in increased activity of CASP9 protein]]; TYMP inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]; TYMP protein inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]
